Relative Initial Weight Is Associated with Improved Survival without Altering Tumor Latency in a Translational Rat Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma and Transarterial Embolization

J Vasc Interv Radiol. 2017 Jul;28(7):1043-1050.e2. doi: 10.1016/j.jvir.2017.03.037. Epub 2017 May 9.

Abstract

Purpose: To test the hypotheses that (i) heavier rats demonstrate improved survival with diminished fibrosis in a diethylnitrosamine (DEN)-induced model of hepatocellular carcinoma (HCC) and (ii) transarterial embolization via femoral artery access decreases procedure times versus carotid access.

Materials and methods: One hundred thirty-eight male Wistar rats ingested 0.01% DEN in water ad libitum for 12 weeks. T2-weighted magnetic resonance imaging was used for tumor surveillance. Rats underwent selective embolization of ≥ 5 mm tumors via carotid or femoral artery catheterization under fluoroscopic guidance. Rats were retrospectively categorized into 3 groups by initial weight (< 300, 300-400, > 400 g) for analyses of survival, tumor latency, and fibrosis. Access site was compared relative to procedural success, mortality, and time.

Results: No significant differences in tumor latency were related to weight group (P = .310). Rats weighing < 300 g had shorter survival than both heavier groups (mean, 88 vs 108 d; P < .0001), and more severe fibrosis (< 300 g median, 4.0; 300-400 g median, 1.5; > 400 g median, 1.0; P = .015). No significant difference was found in periprocedural mortality based on access site; however, procedure times were shorter via femoral approach (mean, 71 ± 23 vs 127 ± 24 min; P < .0001).

Conclusions: Greater initial body weight resulted in improved survival without prolonged tumor latency for rats with DEN-induced HCCs and was associated with less severe fibrosis. A femoral approach for embolization resulted in decreased procedure time. These modifications provide a translational animal model of HCC and transarterial embolization that may be suited for short-term survival studies.

MeSH terms

  • Animals
  • Body Weight*
  • Carcinoma, Hepatocellular / therapy*
  • Diethylnitrosamine
  • Disease Models, Animal
  • Embolization, Therapeutic / methods*
  • Fibrosis
  • Fluoroscopy
  • Liver Neoplasms / therapy*
  • Magnetic Resonance Imaging
  • Male
  • Rats
  • Rats, Wistar
  • Retrospective Studies
  • Survival Rate

Substances

  • Diethylnitrosamine